Mannkind looking to use its inhaler in new therapeutic areas, not just diabetes

After several regulatory delays, Mannkind ($MNKD) finally got its Afrezza inhaled insulin past the FDA. With the help of marketing partner Sanofi ($SNY), the company posted Afrezza shipments worth $13 million in the first half of the year, though it still experienced a net loss of $28.9 million in Q2. Looking forward, the company aims to use its delivery tech to treat a variety of conditions, potentially including pain, pulmonary-related diseases, central nervous system diseases and nicotine addition. One advantage of the inhaled administration pathway is that drugs don't come into contact with the liver, which is helpful for those that are toxic to that organ. "We're trying to build a portfolio of probably about four to 6 products that we will pursue," Mannkind CEO Hakan Edstrom said. "Not all of them will be successful, but you've got to start and then hope that you reach all the way through regulatory approval to the market." More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.